MARKET

BIAF

BIAF

bioAffinity Tech
NASDAQ
1.510
-0.090
-5.63%
After Hours: 1.510 0 0.00% 17:40 06/09 EDT
OPEN
1.615
PREV CLOSE
1.600
HIGH
1.615
LOW
1.450
VOLUME
124.87K
TURNOVER
--
52 WEEK HIGH
13.80
52 WEEK LOW
0.6930
MARKET CAP
6.85M
P/E (TTM)
-0.1334
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BIAF last week (0601-0605)?
Weekly Report · 1d ago
BioAffinity Technologies announces SAB to host webinar on CyPath Lung
TipRanks · 06/02 13:22
bioAffinity Showcases CyPath Lung in Upcoming Clinical Webinar
TipRanks · 06/02 13:01
bioAffinity to present CyPath Lung test in Society for Advanced Bronchoscopy webinar
PUBT · 06/02 12:03
Weekly Report: what happened at BIAF last week (0525-0529)?
Weekly Report · 06/01 10:00
BioAffinity Technologies announces notification of Mexico patent allowance
TipRanks · 05/27 14:25
bioAffinity Gains Mexican Patent for CyPath Lung Diagnostic
TipRanks · 05/27 13:00
bioAffinity Receives Mexican Institute Of Industrial Property Allowance For A Patent Application Regarding Methods Of Predicting The Likelihood Of Lung Cancer Using Flow Cytometry
Benzinga · 05/27 12:07
More
About BIAF
bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.

Webull offers bioAffinity Technologies Inc stock information, including NASDAQ: BIAF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIAF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIAF stock methods without spending real money on the virtual paper trading platform.